Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
FBR Capital Remains Bullish on Advaxis (ADXS) Following Conference Call About FDA IND Clinical Hold
October 7, 2015 7:49 AM EDTFBR Capital reiterated an Outperform rating and $34.00 price target on Advaxis (NASDAQ: ADXS) following a conference call and webcast. The call was to discuss the announcement that its Investigational New Drug (IND) application for axalimogene filolisbac (AF) was placed on clinical hold by the FDA, affecting four clinical trials with AF in cervical cancer.
Analyst Vernon Bernardino commented, "Advaxis, after market... More
